எழுத்தாளர் சிகிச்சை News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Insider s Top Healthcare Stories for the Week Ending August 20
businessinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businessinsider.com Daily Mail and Mail on Sunday newspapers.
Anaerobic methane oxidation exerts a key control on greenhouse gas emissions
1, yet factors that modulate the activity of microorganisms performing this function remain little explored. In studying groundwater, sediments, and wetland soil where methane production and oxidation occur, we discovered extraordinarily large, diverse DNA sequences that primarily encode hypothetical proteins. Four curated, complete genomes are linear, up to ~1 Mbp in length and share genome organization, including replicore structure, long inverted terminal repeats, and genome-wide unique perfect tandem direct repeats that are intergenic or generate amino acid repeats. We infer that these are a new type of archaeal extrachromosomal element with a distinct evolutionary origin. Gene sequence similarity, phylogeny, and local divergence of sequence composition indicate that many of their genes were assimilated from methane-oxidizing
Scribe Therapeutics continues to advance the development of its CRISPR platform and pipeline
Company was co-founded by Jennifer Doudna, a co-inventor of CRISPR technology
Scribe Therapeutics has completed an oversubscribed $100m Series B financing round to advance the development of its CRISPR platform and pipeline.
Scribe was co-founded by Jennifer Doudna, a co-inventor of CRISPR technology and co-recipient of the 2020 Nobel Prize in Chemistry.
The company’s platform is based on CRISPR technology (also known as CRISPR-Cas9) – CRISPRs are specialised stretches of DNA that can be cut by Cas9 enzymes.
This technology evolved from the natural defence mechanisms of bacteria and archaea, which use RNA and Cas proteins to target and attack viruses and other foreign bodies.
Trotz Biotech-Hype: Buffett-Investment Biogen bleibt hinter Mitbewerbern zurück
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
Dec 17, 2020 at 6:29PM
Biogen (NASDAQ:BIIB) had a wild 2020. In November, reviewers from the Food and Drug Administration (FDA) seemed to endorse the company s potential Alzheimer s drug aducanumab, sending the shares up 44%. A few days later, an advisory panel overwhelmingly said there was not strong evidence that the drug was effective, sending shares back down.
An official decision will come by March. While investors wait, a lot is happening at the $36 billion biotech company.
Image source: Getty Images
Competition heats up
Biogen is primarily focused on neurological disorders, with most of its $14.3 billion annual revenue coming from multiple sclerosis (MS) drugs. For the first nine months of 2020, the MS drugs have declined less than 1%. But things are starting to get worse.
vimarsana © 2020. All Rights Reserved.